CA1189794A - Compose pour le traitement du prurit - Google Patents

Compose pour le traitement du prurit

Info

Publication number: CA1189794A
Authority: CA; Canada
Prior art keywords: naloxone; composition; pharmaceutically acceptable; pruritis; itching
Prior art date: 1983-03-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000423216A

Other languages

English (en)

Inventor

Joel E. Bernstein

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Dermall Ltd

Original Assignee

Dermall Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-03-09

Filing date

1983-03-09

Publication date

1985-07-02

1983-03-09 Application filed by Dermall Ltd filed Critical Dermall Ltd

1983-03-09 Priority to CA000423216A priority Critical patent/CA1189794A/fr

1985-07-02 Application granted granted Critical

1985-07-02 Publication of CA1189794A publication Critical patent/CA1189794A/fr

Status Expired legal-status Critical Current

Links

208000003251 Pruritus Diseases 0.000 title claims abstract description 21
239000000203 mixture Substances 0.000 title claims description 8
229960004127 naloxone Drugs 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 9
239000006071 cream Substances 0.000 claims abstract description 7
239000002674 ointment Substances 0.000 claims abstract description 7
239000000243 solution Substances 0.000 claims abstract description 7
239000006210 lotion Substances 0.000 claims abstract description 6
RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 claims description 17
229960005250 naloxone hydrochloride Drugs 0.000 claims description 5
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 4
229960003086 naltrexone Drugs 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 2
230000000699 topical effect Effects 0.000 abstract description 5
239000000126 substance Substances 0.000 abstract description 2
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 abstract 1
230000007803 itching Effects 0.000 description 13
239000000739 antihistaminic agent Substances 0.000 description 5
229940125715 antihistaminic agent Drugs 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
201000005962 mycosis fungoides Diseases 0.000 description 3
230000003533 narcotic effect Effects 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
208000024780 Urticaria Diseases 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010003399 Arthropod bite Diseases 0.000 description 1
241000255925 Diptera Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
239000003887 narcotic antagonist Substances 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000008306 shake lotion Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229940025703 topical product Drugs 0.000 description 1
230000002568 urticarial effect Effects 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000423216A 1983-03-09 1983-03-09 Compose pour le traitement du prurit Expired CA1189794A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000423216A CA1189794A (fr)	1983-03-09	1983-03-09	Compose pour le traitement du prurit

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000423216A CA1189794A (fr)	1983-03-09	1983-03-09	Compose pour le traitement du prurit

Publications (1)

Publication Number	Publication Date
CA1189794A true CA1189794A (fr)	1985-07-02

Family

ID=4124743

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000423216A Expired CA1189794A (fr)	1983-03-09	1983-03-09	Compose pour le traitement du prurit

Country Status (1)

Country	Link
CA (1)	CA1189794A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN115397419A (zh) *	2020-02-14	2022-11-25	帝国制药美国公司	外用纳洛酮组合物及其使用方法

1983
- 1983-03-09 CA CA000423216A patent/CA1189794A/fr not_active Expired

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN115397419A (zh) *	2020-02-14	2022-11-25	帝国制药美国公司	外用纳洛酮组合物及其使用方法
US12364692B2 (en)	2020-02-14	2025-07-22	Teikoku Pharma Usa, Inc.	Topical naloxone compositions and methods for using the same

Similar Documents

Publication	Publication Date	Title
US4416886A (en)	1983-11-22	Method of treating pruritis and composition therefor
DE69017596T2 (de)	1995-07-06	Verwendung eines Opiatantagonisten zur Herstellung eines transdermal zu verabreichenden Arzneimittels sowie eine Vorrichtung zur transdermalen Verabreichung.
DE60022021T2 (de)	2006-06-08	Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion
US4518789A (en)	1985-05-21	Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use
US5244902A (en)	1993-09-14	Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US4880813A (en)	1989-11-14	Method of treatment for allergic rhinitis
CA1320445C (fr)	1993-07-20	Compositions ayant un effet sur la suppression de l'hypersensibilite retardee cutanee et produits les renfermant
US5866143A (en)	1999-02-02	Topical application of opioid drugs such as morphine for relief of itching and skin disease
DK159757B (da)	1990-12-03	Anvendelse af naphthalenderivater til fremstilling af et medikament til behandling eller profylakse af inflammation ved topisk administration og farmaceutisk praeparat til topisk anvendelse indeholdende naphthalenderivaterne
DE69522188T2 (de)	2001-11-29	Verwendung von Substanz P Antagonist im pharmazeutischer Zusammensetzung
EP3677265A1 (fr)	2020-07-08	Composition pour prévenir ou traiter les troubles du sommeil
WO1984000889A1 (fr)	1984-03-15	Methode et medicament de traitement du prurit
Georgitis et al.	1994	Ipratropium bromide nasal spray in non‐allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life
US4395420A (en)	1983-07-26	Method and composition for treating pruritis
US20030054030A1 (en)	2003-03-20	Method and compositions for the treatment of pruritus
CA2015585C (fr)	1995-10-24	Methode et compose pour le traitement des troubles dermatologiques a mediation par les mastocytes
CA1189794A (fr)	1985-07-02	Compose pour le traitement du prurit
JP2001515479A (ja)	2001-09-18	偏頭痛治療におけるレボブピバカインまたはロピバカインの使用
JPH03291221A (ja)	1991-12-20	皮膚外用液剤
US4315024A (en)	1982-02-09	Compositions and method for treating red eye
JPH08291057A (ja)	1996-11-05	パップ剤
US6096738A (en)	2000-08-01	Method for treatment of headache
JPH11505238A (ja)	1999-05-18	皮膚症状処置用組成物
JPH04501851A (ja)	1992-04-02	脱毛症治療のためのミノキシジルおよび血管収縮薬組成物
RU2426540C1 (ru)	2011-08-20	Противовоспалительное и противоаллергическое лекарственное средство и фармацевтическая композиция на его основе

Legal Events

Date	Code	Title	Description
2002-07-03	MKEC	Expiry (correction)
2003-03-09	MKEX	Expiry